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Abstract

Author Manuscript

The heart-specific isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) is
an important regulator of glycolytic flux in cardiac cells. Here, we present the crystal structures of
two PFKFB2 orthologues, human and bovine, at resolutions of 2.0 and 1.8Å, respectively. Citrate,
a TCA cycle intermediate and well-known inhibitor of PFKFB2, co-crystallized in the 2-kinase
domains of both orthologues, occupying the fructose-6-phosphate binding-site and extending into
the γ-phosphate binding pocket of ATP. This steric and electrostatic occlusion of the γ-phosphate
site by citrate proved highly consequential to the binding of co-complexed ATP analogues. The
bovine structure, which co-crystallized with ADP, closely resembled the overall structure of other
PFKFB isoforms, with ADP mimicking the catalytic binding mode of ATP. The human structure,
on the other hand, co-complexed with AMPPNP, which, unlike ADP, contains a γ-phosphate. The
presence of this γ-phosphate made adoption of the catalytic ATP binding mode impossible for
AMPPNP, forcing the analogue to bind atypically with concomitant conformational changes to the
ATP binding-pocket. Inhibition kinetics were used to validate the structural observations,
confirming citrate’s inhibition mechanism as competitive for F6P and noncompetitive for ATP.
Together, these structural and kinetic data establish a molecular basis for citrate’s negative feedback loop of the glycolytic pathway via PFKFB2.
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Introduction
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The bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB),
catalyzes both the synthesis and hydrolysis of fructose-2,6-bisphosphate (Fru-2,6-P2) as a
functional homodimer (C. Wu et al. 2006). The dual enzymatic activities are provided by the
two separate catalytic domains existing in a single protein subunit, to control the
concentration of Fru-2,6-P2, the most potent allosteric activator of 6-phosphofructo-1-kinase
(PFK), the rate-limiting enzyme of glycolysis (El-Maghrabi and Pilkis 1984; Pilkis and
Granner 1992; Pilkis et al. 1995). An elevated cellular concentration of Fru-2,6-P2 increases
glycolytic flux, whereas a lowered concentration of Fru-2,6-P2 decreases glycolysis.
Reflecting the diversity of tissues and their physiological functions, different tissue-specific
isoforms of PFKFB from four distinct genes (pfkfb1-4) are expressed, each with different
kinetic properties, and a single isoform generally predominates in each tissue: PFKFB1, the
liver form; PFKFB2, the heart form; PFKFB3, the inducible form; and PFKFB4, the testis
form (Okar et al. 2001).
Because of the uniqueness in its structure/function relationships, the PFKFB enzyme system
has long been the target of structure/function studies. As a result, a significant amount of
functional data has been produced and the crystal structures of the rat liver Fru-2,6-P2ase
domain, the rat testis form (PFKFB4), the human liver form (PFKFB1), and human cancer
form (PFKFB3) have been determined (Hasemann et al. 1996; Kim et al. 2006; Y. H. Lee et
al. 2003). These data altogether allowed us to understand the molecular mechanism of
catalytic reactions and regulation of this enzyme system. Some are now serving as a
molecular foundation for development of therapeutics for diabetes and cancer (Garber 2004;
A. Minchenko et al. 2002).
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However, one of the most fundamental questions yet to be answered about this enzyme
system is how each PFKFB isoform performs its differential function in hosting tissues that
have specific physiological roles and, accordingly, different optimum conditions for glucose
metabolism. Reflecting such differences, the PFKFB isozymes have been shown to have
different kinetic properties, as summarized in Figure 4.5. These kinetic differences suggest
that glucose metabolism is uniquely related to the physiological roles of the given tissues
and not just a simple housekeeping function for energy production (Y. H. Lee et al. 2003;
Pilkis et al. 1995).

Author Manuscript

As an effort to address the tissue-type specifically differentiated structure/function
relationships of PFKFB isoforms, we determined the crystal structures of heart isoforms of
PFFKB, PFKFB2, from both H. sapiens and B. taurus. Analysis of their structures and
kinetics in comparison with those already known from the previous PFKFB studies
suggested a regulatory mechanism as yet unknown and we introduce the results here.

Materials and Methods
Crystallization of PFKFB2 Homologs
DNA sequences encoding full length constructs of the human and bovine PFKFB2 isoforms
were cloned into a pET-3a vector (Novagen) allowing fusions to a 6xHis tag sequence at the
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N-termini. Both proteins were overexpressed in Escherichia coli BL21 C41(DE3) using
0.3mM IPTG at 18°C and purified using Ni-NTA affinity columns in conjunction with SP
Sepharose cation exchange columns. Following purification by SP Sepharose, the proteins
were dialyzed with pH 8.0 20 mM Tris•HCl, 10 mM NaPi, 5 mM β-Mercaptoethanol, and
5% glycerol and then concentrated to 8.0 mg/ml with Millipore centrifugal filter
concentrators. Crystallization of the bovine PFKFB2 (bPFKFB2) were prepared via sitting
drop vapor diffusion using a 1:1 mixture of protein sample to a mother liquor, pH 7.5
100mM HEPES, pH 7.0 0.5% tacsimate, 13–16% polyethylene glycol 3350, and 3%
dioxane. The crystals were grown to a dimension of 0.2 × 0.2 × 0.05 mm within 2–3 weeks
of incubation at 20°C. Crystals of the human PFKFB2 (hPFKFB2) were also prepared with
the sitting drop vapor diffusion method using a mother liquor, pH 6.0 100mM MES, 0.5–
3.0% polyethylene glycol 8000, 13–16% polyethylene glycol 3350, and 3% dioxane. Data
quality crystals of hPFKFB2 were grown after 3–5 weeks of incubation at 12°C.
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Data Collection and Processing
The crystals were soaked for cryo-protection and liganding in cryoprotectant solutions,
containing the aimed ligands, for 0.5 to 2 hours prior to flash freezing at 77K using liquid
N2. All cryoprotectant solutions were prepared by enriching the reservoir solution of each
crystal with 35% ethylene glycol. The diffraction data was collected at both beamline 6C of
the Pohang Accelerator Laboratory, Pohang, Korea, using the CCD detector Quantum 210
(ADSC) with a source wavelength of 1.23986 Å or at the Gulf Coast Consortium Protein
Crystallography Beamline (PX1) in the Center for Advanced Microstructures and Devices
(CAMD), Louisiana State University, Baton Rouge, LA., using a Mar 165 mm CCD detector
with a source wavelength of 1.3808 Å. All diffraction data was processed and scaled using
HKL2000.
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Crystals of hPFKFB2 belong to the primitive orthorhombic space group P212121, having
unit cell dimensions of a = 106.5 Å, b = 113.9 Å, c = 133.2 Å and an asymmetric unit
consisting of two monomers. Crystals of bPFKFB2 belong to the C-centered orthorhombic
space group, C2221, with unit cell dimensions being a = 82.1 Å, b = 169.5 Å, c = 85.3 Å, α
=90, β =90, γ =90 and an asymmetric unit consisting of one monomer. Statistics of the
reflection data are summarized in Table 1.
Structure determination and refinement
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The structures of hPFKFB2 and bPFKFB2 were determined by molecular replacement using
the Phaser software module implemented in the PHENIX program suite. Initial models for
both orthologues were determined using the human liver PFKFB (1K6M) as a search model
(Y. H. Lee et al. 2003). The final structures were achieved after iterated model rebuilding
and refinement using PHENIX and Coot (P. D. Adams et al. 2010; Emsley and Cowtan
2004). The Rcrys/Rfree of the final models are 0.202/0.225 and 0.156/0.211 for hPFKFB2
and bPFKFB2, respectively.
The final models revealed the residues 31–450 out of 505 of hPFKFB2 and those of 28–450
of bPFKFB2. The missing residues are all from both the N- and C-terminal regulatory
domains and are considered disordered, based on the results from mass spectroscopy of melt
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crystals (data not shown). For the human model, 93.2% of the 420 revealed residues lie
within the ‘most favorable region’ of the main chain dihedral angle distribution, whereas
none are found in the ‘disallowed region’. Similarly, for the 423 residues of the bovine
orthologue, 90.9% are within the “most favorable region” and none are in the “disallowed
region”.
Biochemical Assays
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The 2-kinase inhibition assays were performed using a Fru-2,6-P2 assay modified for 96well plates from the conventional method for both the wildtype hPFKFB2 and Y428A
mutant (Van Schaftingen E, et al.). This assay consisted of two sequential steps: Fru-2,6-P2
production by PFKFB2 and allosteric activation of PFK-1 by the produced Fru-2,6-P2. For
the first reaction, Fru-2,6-P2 synthesis by PFKFB2, was started by adding 130 nM PFKFB2
to mixtures containing 20 mM pH 8.0 TES, 1 mM DTT, 2 mM MgCl2, 0.5% tween, and
varying concentrations of citrate, ATP and Fru-6-P, ranging from 0 to 200 mM for each. This
reaction was allowed to run for 10 minutes at 25°C and then stopped by the addition of 0.1
M KOH. Aliquots of 1–4 μL of the first reaction were transferred, after pH neutralization, to
the reactions of the second step, which consisted of 50 mM pH 8.0 Tris•HCl, 0.2 mM
NADH, 5 mM DTT, 1 mM F-6-P, 2 mM MgCl2, 0.70 units/mL Aldolase, 0.45 units/mL
glyceraldehyde dehydrogenase, 0.60 units/mL triose-phosphate isomerase, and 10 mU
pyrophosphate-dependent phosphofructokinase. The reactions of second step were started by
adding 0.5 mM sodium pyrophosphate and were then measured for changes in absorbance at
340 nm over a period of 30 minutes.
Accession numbers
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Protein Data Bank: Coordinates and structure factors were deposited with the following
codes: H5R5 (Bovine PFKFB2) and 5HTK (Human PFKFB2).

Results and Discussion
Overall Structures of PFKFB2
As summarized in the previous section and Table 1, crystal structures of the two PFKFB2
orthologs were determined – human (hPFKFB2) to 2.0Å and bovine (bPFKFB2) to 1.8Å –
to elucidate any structural/functional differences in heart-type PFKFB compared to other
isoforms. Similar to the other PFKFB isoforms, the crystal structure of the heart isozyme,
for both human and bovine orthologues, shows a PFKFB-typical head-to-head homodimer
arrangement (Figure 1a) with a dimeric interface constituted primarily through crystal
contacts made between two kinase domains.

Author Manuscript

Each PFKFB2 monomer consists of a single polypeptide chain that can be subdivided into
four distinct regions: the 6-phosphofructo-2-kinase (2-Kase) domain, the fructose-2,6bisphosphatase (2-Pase) domain, and two regulatory domains. The two catalytic domains are
conserved among the different tissue isoforms with the sequence identity 76–83%, whereas
the N-terminal and C-terminal domains are highly variable. Among 505 amino acid residues
of PFKFB2, residues 1–37 and 451–505 constitute the N- and C-terminal regulatory
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domains, whereas residues 38–248 and 249–450 constitute the 2-Kase and 2-Pase domains,
respectively.
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The sequence identity shared between the human and bovine orthologs is larger than 95%,
supporting the notion that the two PFKFB2 orthologs play a physiological role common to
both human and swine. To analyze the structural differences between the two orthologs, Cα
traces of hPFKFB2’s 2-Kase and 2-Pase domains were superimposed, separately, onto
corresponding domains of bPFKFB2 (Figure 1b). It was not appropriate to compare the two
domains together, because differences in liganding states of the orthologs cause differences
in the domain-domain interface. In agreement with the high sequence identity, the two
catalytic domains showed a high degree of overall similarity, with RMSD values of 1.46 Å
and 0.68 Å, for the 2-Kase and 2-Pase domains, respectively. Although the discrepancy in
the 2-Kase domains is higher than expected, no significant structural differences between the
two orthologs, which would implicate coinciding differences in the structure/function
relationship, are apparent.
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The unexpectedly high RMSD for the 2-Kase domains is likely due to differences in
liganding states of the two orthologs despite sharing similar liganding conditions during
crystallization. For both the structures, Fru-6-P and citrate were in common, whereas
AMPPNP – a non-hydrolyzable ATP analog – and ADP were exclusively included fill the
ATP pockets of hPFKFB2 and bPFKFB2, respectively. Structural dissimilarities were
concentrated to localized regions within-or-near the 2-Kase’s active site and correlate with
citrate’s binding to the 2-Kase domain. Despite Fru-6-P being present in crystallization
conditions for both orthologues, it didn’t complex with the 2-kinase domain of either,
regardless of concentration. Instead, citrate, from an earlier purification step, occupies the
Fru-6-P binding pocket. Interestingly, the binding of citrate appears to significantly
influence ATP but not ADP binding to the 2-Kase domain. The details will be discussed in
the following sections.
As indicated in Table 1, His258 were found as phosphorylated histidine in both the
structures despite the fact that no Fru-2,6-P2 was involved in crystallization attempts. No
other isoforms have shown phosphorylated histidine unless the crystals are soaked with high
concentrations of Fru-2,6-P2 to induce the phosphorylated histidine as a catalytic
intermediate state (Kim et al. 2007). The only possibility is that the phosphorylated histidine
was formed by Fru-2,6-P2 synthesized during the PFKFB2 expression in E. coli. In addition,
it has to be presumed that PFKFB2 has the phosphor-histidine state, which is more stable
than that of any other isoforms.
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Citrate binding to the 2-Kase domain
There was no Fru-6-P molecule bound to the 2-Kinase domain despite being present in the
crystallization mixture, because the 2-Kase, which follows an ordered reaction, requires ATP
binding prior to Fru-6-P binding. Instead, citrate was found to be bound to the Fru-6-P
pocket of the 2-Kase domains of both hPFKFB2 and bPFKFB2 with strong hydrogen bonds
to Thr130 and Tyr197 and salt bridges with Arg78 and Arg102 (Figure 2a). Except for
Arg102, which is conserved though, all of these residues are known to be involved in the
catalytic binding of Fru-6-P to the 2-Kase domain. This binding mode of citrate is conserved
Proteins. Author manuscript; available in PMC 2017 January 01.
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between the bovine and human orthologs. It is known that the 2-Kase of PFKFB2, the heart
isoform, is very sensitive to inhibition from products of TCA cycle such as succinate and
citrate. A previous structural study has suggested that succinate behaves like a competitive
inhibitor against Fru-6-P (Galluzzi et al. 2013).

Author Manuscript

However, citrate bound to PFKFB2 suggests an inhibition pattern, which is different from
that of succinate, which was previously studied (Yuen et al. 1999). While primarily located
in the Fru-6-P binding site, citrate, unlike succinate, impedes the γ-phosphate of AMPPNP
from occupying its normal location for the Fru-2,6-P2 synthesis. When citrate from
hPFKFB2 was superimposed onto a pseudo-Michaelis complex of PFKFB3 (2DWP), one of
the three carboxy group arms of citrate is only 1.2Å away from the γ-phosphate of
AMPPCP (Figure 2b) (Kim et al. 2007). Such close proximity of two negatively charged
acidic groups is both sterically and electrostatically unfavorable for ATP binding but ADP
binding is not significantly influenced. Thus, it has been suggested that ATP binding to the
2-Kase domain in the known catalytic mode is not favored in the presence of citrate. And,
considering perfect conservation of all the residues for citrate, binding of citrate to the four
PFKFB isoforms would be very similar.
Conserved catalytic binding of ATP and ADP to the 2-Kase domain
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Both hPFKFB2 and bPFKFB2 were co-crystallized in the presence of ADP and AMPPNP,
respectively. As expected, the binding of ADP in the bPFKFB2 structure is analogous to the
catalytic mode of ADP and ATP, which were well characterized and elucidated in previous
studies of the PFKFB protein system (Figure 3a) (Kim et al. 2007; Y. H. Lee et al. 2003).
The adenine moiety resides in a partly solvent-exposed hydrophobic pocket stabilized
primarily through CH-π contributions made by Gly51, Tyr54, and Val221. A single
hydrogen bond is formed between the adenine N6 and the Oδ of Asn168. The nucleotide
diphosphates, on the other hand, occupy a highly anionic phosphate binding loop created by
a Walker A motif – conserved as -49GLPARGKT56- in all PFKFB isoforms (Walker et al.
1982). Additional hydrogen bonds to the phosphate moieties are contributed from the side
chains of Lys172 and Tyr428. This binding is well conserved among all PFKFB isoforms.
However, Tyr428 plays a different role upon binding of AMPPNP in the presence of citrate
bound to 2-Kase.
An alternative ATP binding mode to the 2-Kase domain caused by citrate binding
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Surprisingly, the binding mode of AMPPNP in the presence of citrate is markedly different
from the conventional mode of catalytic ATP binding for the Fru-2,6-P2 synthesis, when it
was revealed by the |Fo| - |Fc| omit map (Figure 3c). When AMPPNP from the
hPFKFB2•AMPPNP complex was superimposed onto ADP of bPFKFB2•ADP complex, as
can be seen in Figure 3b, the ribose and adenine rings of AMPPNP are rotated 115° and
180°, respectively, relative to those of ADP. Furthermore, the centroid of AMPPNP’s
adenine ring is 14Å shifted outward from that of ADP. Consequently, few molecular
interactions are shared among the bindings of adenosine moieties of AMPPNP and ADP to
PFKFB2 and, thus, the nucleoside binding sites for AMPPNP are remarkably different from
that of ADP (Figure 3c). From the AMPPNP-complexed structure, it can be seen that the αcarbon of Pro176 shifts ~3.3Å, placing the residue’s R-group perpendicular to AMPPNP’s
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planar ring, allowing for CH-π contributions. More significant contributions come by way of
π-π stacking interactions with the phenol side chain of Tyr428, which is otherwise involved
in interaction with the phosphate moieties. For the π-π stacking between the adenine ring
and Tyr428, the β-hairpin containing Tyr428 shifted 4Å and the phenol sidechain rotated
away from the position for its conventional interaction with the α-phosphate moiety of ADP
(Figure 3d).
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As a consequence, the γ-phosphate of AMPNP occupies the site for the β-phosphate of
ADP or catalytic ATP, sharing many contact residues with the α- and β-phosphates of ADP.
Of the five residues forming the Walker A motif, Tyr54 is the only notable absence. As for
sidechain interactions, the phosphate stabilizing hydrogen bond of Tyr428 is replaced by
Ser174. Interactions with Lys172, on the other hand, are completely lost, with the residue
flipping outward towards the solvent. This atypical binding of AMPPNP is inappropriate for
the 2-Kase catalytic reaction and appeared to be caused by the citrate binding to 2-Kase as
described in the following section.
Citrate inhibition at the active site of the 2-Kinase domain

Author Manuscript

Although previous studies have reported citrate to inhibit PFKFB enzymes, particularly the
heart isotype, the inhibition mechanism has remained unknown (Ros and Schulze 2013).
From the human structure of PFKFB2 presented here, it can now be seen that citrate
competitively blocks F6P binding while simultaneously prohibiting ATP, or any γ-phosphate
containing analogues, from binding in a catalytically active position. Inhibition studies were
conducted to validate these structural observations. Non-linear regression analyses of the
data supported the structural findings, showing citrate to act as a competitive inhibitor for
F6P with a Ki of 80.3±6.5μM and non-competitive inhibitor for ATP with a Kis of
50.23±8.0μM and Kii of 58.75±9.9μM, as shown in the double-reciprocal plot (Figure 4) and
summarized in Table 2. It was well accepted that PFKFB3 catalyzes the reaction of Fru-2,6P2 synthesis with ordered bindings of ATP first and then Fru-6-P. Because citrate can bind to
both the free enzyme (E) and the ATP bound enzyme (E•ATP), citrate is a non-competitive
inhibitor. The noncompetitive inhibition agrees with the observation that citrate influences
but does not completely block ATP from binding.
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To validate biological significance of the citrate binding and the consequentially altered
binding of ATP, a site-directed mutant, Y428A, the π-π stack provider for the altered ATP
binding mode was mutated to alanine, was prepared and its kinetic properties were analyzed
in comparison to the wild-type, as shown in Table 2. The Y428A mutant PFKFB2 exhibited
kinetic properties, which are uniquely different from those of the wild type. Although the
change in Km for ATP is modest, a 6-fold increase in its affinity for Fru-6-P and a near 10fold increase in its kcat were observed. The activity increase was probably driven by an
increased affinity for Fru6-P, although a notable 20-fold increase in affinity for the inhibitor,
citrate, from 50.2 μM to 2.4 μM was also observed as counteract. This difference is likely
attributable to a reduction in the non-catalytic, inhibitory binding of ATP in response to the
lost π-π stacking interactions between phenyl ring and the adenine base of the inhibitory
ATP binding.
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The apparent differences in kinetic properties between wild-type and the mutant strongly
suggest that Tyr428 makes significant contributions to citrate inhibition of 2-Kase by
allowing ATP to bind in a non-catalytic, inhibitory fashion. As a consequence, citrate is not
only an apparent competitive inhibitor against Fru-6-P but also makes ATP act as an
apparent inhibitor. The present study suggests that the inhibitory ATP binding significantly
depends on Tyr428 mediated π-π stack interactions between the adenine base moiety of
ATP and the tyrosine side chain. When these π-π stacking interactions were prevented, as
with the Y428A mutant, the inhibitory binding of ATP was decreased, making the overall
inhibition potency of citrate weaker. In addition, it is likely that the mutant have a difference
in the conformational change required for ordered bindings of ATP and Fru-6-P, because
Tyr428 is an important residue for ATP binding. As consequence, the Fru-6-P pocket is more
stable such that bindings of both Fru-6-P and citrate are increased as manifested in their Km
and Ki, respectively.
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The suggested model is in agreement with the previously accepted model of energy
metabolism within cardiac cells. It has been well established that the heart cells depend
mainly on oxidation of fatty acids and ketone bodies as energy source and that glycolysis is
mostly down regulated in the heart through the so called “glucose-sparing effect”. This
suggests a possible model of the glucose-sparing effect. An unnecessary increase in the
myocardial levels of Fru-2,6-P2, the most potent allosteric activator of the glycolysis rateregulator protein, phosphofructokinase, is avoided by the citrate-sensitive 2-Kase domain in
PFKFB2 isoform.
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PFKFB2

Heart-type 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase PFKFB3

F-6-P

fructose-6-phosphate

F-2,6-P2

fructose-2,6-bisphosphate

AMPPNP

Adenylyl-imidodiphosphate
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Highlights
•

Solved the crystal structure of PFKFB2.

•

Structurally determined the molecular basis for citrate’s inhibition of
PFKFB2.

•

Validated citrate’s inhibition model using enzyme kinetics.

•

Demonstrated that citrate binding induces ATP to bind in a noncatalytic, inhibitory fashion.
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Figure 1.

Dimeric arrangement of heart form and a comparison of the structures of the human and
bovine orthologues. (A) Head-to-head homodimer arrangement of the human PFKFB2.
Shown in gray is a complete monomer, while the red and blue colors depict the 2-Kase and
2-Pase domains, respectively. Ligands are colored by element and are shown in stick form.
(B) Superimposed C-alpha traces of bovine (blue) and human (light gray) kinase and
phosphatase domains. The phosphatase domains contain Fru-6-P from the bovine orthologue
in the F-2,6-P2 binding site. The kinase domains with ADP and Citrate from the bovine
orthologue in the ATP and F6P binding sites, respectively.
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Citrate binding in the 2-Kase domain. (A) Superimposed structures of the citrate binding
pocket for human (blue) and bovine (light gray) orthologues. Residues forming interactions
with citrate are represented as sticks, with a ribbon diagram representing the mainchain.
Human PFKFB2 is depicted as a blue ribbon with sticks containing green carbon atoms. In
contrast, bovine PFKFB2 is represented as a light gray ribbon with sticks containing white
carbon atoms. (B) AMPPCP and F6P from PFKFB3 (2DWP) overlaid onto the citrate
binding site of human PFKFB2. The distance between the carboxy arm from citrate and
nearest atom from the overlaid AMPPCP is shown. Both AMPPCP and F6P are semitransparent colored orange.
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Ligand Binding within the 2-Kase Domain. (A) Bovine PFKFB2 complexed with ADP and
Citrate. Superimposed are AMPPCP and F6P from the pseudo-substrate complex with
PFKFB3 (2DWP), showing the catalytic ATP and F6P binding modes, respectively. (B)
Human PFKFB2 complexed with AMPPNP and Citrate. Superimposed are AMPPCP and
F6P from the pseudo-substrate complex with PFKFB3 (2DWP), showing the catalytic ATP
and F6P binding modes, respectively. (C) Unbiased Fo-Fc omit map of AMPPNP and
neighboring residues in human PFKFB2. Contoured at 3.0σ (D) Ribbon diagram view of
human PFKFB2 (blue) super-imposed onto the bovine orthologue (light gray). The
sidechains and their positional differences are shown for residues involved in AMPPNP
binding.
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2-Kase inhibition by Citrate. (A) Double reciprocal plot with F6P as the variable substrate
showing competitive inhibition, where v=Vmax[S]/{Km(1+[I]/Kis)+[S]} (B) Double
reciprocal plot with ATP as the variable substrate showing non-competitive inhibition, where
v=Vmax[S]/{Km(1+[I]/Kis)+[S](1+[I]/Kii)}.
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Citrate inhibition properties on wild-type and mutant PFKFB2.
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